Summary: The Centers for Medicare & Medicaid Services modified its alpha-fetoprotein coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS alpha-fetoprotein coverage policy has been updated, and if your practice orders or bills AFP testing, this change affects you. The Centers for Medicare & Medicaid Services has modified its coverage determination governing alpha-fetoprotein testing — a marker used in oncology monitoring, prenatal screening, and liver disease workup. The policy does not list specific CPT or HCPCS codes in the available data, so confirm the exact codes with your Medicare Administrative Contractor. The effective date is May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Alpha-fetoprotein |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Oncology, hepatology, gastroenterology, maternal-fetal medicine, laboratory billing |
| Key Action | Review AFP test ordering and billing guidelines before May 15, 2026, and confirm coverage criteria with your MAC |
CMS Alpha-Fetoprotein Coverage Criteria and Medical Necessity Requirements 2026
Alpha-fetoprotein is not a single-use test. Depending on the clinical context, it serves different diagnostic purposes — and CMS evaluates each context separately when it comes to coverage.
The core of any CMS coverage policy for lab testing is medical necessity. For AFP, that means the test must be ordered in response to a specific clinical indication, documented in the medical record, and supported by the treating provider's notes. Ordering AFP as a routine screen without a corresponding diagnosis or clinical rationale is the fastest path to a claim denial.
There are three primary clinical scenarios where AFP testing comes up in Medicare billing. The first is hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis or chronic hepatitis B. The second is monitoring of known germ cell tumors — testicular or ovarian — during and after treatment. The third is prenatal screening, though Medicare's coverage for prenatal indications is limited by the patient population it serves.
Each of these scenarios carries different medical necessity documentation requirements. Your billing team needs to know which clinical context applies to each claim. A claim billed for one indication with documentation supporting a different one is a setup for a denial — or worse, a post-payment audit.
Prior Authorization Under This Coverage Policy
The available policy data does not specify a prior authorization requirement for AFP testing. That said, prior auth requirements can vary by Medicare Advantage plan and by MAC region. Don't assume a fee-for-service Medicare determination applies to your MA patients. Check plan-level requirements separately before May 15, 2026.
Medical Necessity Documentation: What CMS Expects
Medical necessity documentation for AFP should include the treating provider's clinical rationale, the relevant diagnosis, and the frequency justification if the test is ordered on a recurring basis. For HCC surveillance, CMS generally recognizes a six-month interval for high-risk patients. For tumor marker monitoring, the frequency should align with the treatment protocol. One-off orders without clinical context don't hold up under review.
Reimbursement for AFP testing depends on correct diagnosis coding paired with the appropriate lab test code. A mismatched diagnosis — for example, a screening diagnosis on a claim that should reflect a monitoring indication — triggers edits at the MAC level and delays payment.
CMS Alpha-Fetoprotein Exclusions and Non-Covered Indications
The available policy data does not include a detailed exclusions list. However, based on how CMS consistently applies coverage policy to tumor marker and prenatal testing, several non-covered scenarios are predictable.
AFP ordered as a general wellness screen with no documented clinical indication is not covered. Neither is AFP ordered alongside a panel of other tumor markers when there is no active diagnosis or treatment protocol supporting the multi-marker approach. If your practice uses AFP as part of a standing panel without individual medical necessity documentation for each component, review that practice before May 15, 2026.
Prenatal AFP screening is largely outside the Medicare-covered population. If you're billing a prenatal indication under Medicare Part B and expecting routine coverage, that claim is likely to be denied. The clinical context has to match the payer's enrolled population.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HCC surveillance in cirrhosis or chronic hepatitis B | Covered (when medically necessary) | Confirm with MAC | Documentation of diagnosis and surveillance interval required |
| Germ cell tumor monitoring (testicular, ovarian) | Covered (when medically necessary) | Confirm with MAC | Must align with active treatment or follow-up protocol |
| Prenatal screening (Medicare Part B) | Generally not covered | Confirm with MAC | Medicare population typically excludes prenatal indications |
| Routine or wellness screening without clinical indication | Not covered | N/A | No medical necessity basis; claim denial expected |
| Multi-marker panel without individual necessity documentation | Not covered | Confirm with MAC | Each component requires independent medical necessity support |
Note: This policy does not list specific CPT or HCPCS codes in the available data. All code assignments should be confirmed with your MAC before May 15, 2026.
CMS Alpha-Fetoprotein Billing Guidelines and Action Items 2026
The modified coverage policy takes effect May 15, 2026. That gives your billing team time to act — but not much. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Confirm the specific CPT codes your MAC recognizes for AFP billing before May 15, 2026. This policy does not include a code list in the available data. Your MAC's local coverage determination (LCD) may have more specific guidance. Pull it now and compare it against your current charge capture. |
| 2 | Audit your diagnosis coding for AFP claims from the last 90 days. Look for claims where the diagnosis doesn't clearly support the clinical scenario — screening codes on monitoring claims, or vice versa. Fix those patterns before the effective date. |
| 3 | Review your AFP order frequency for HCC surveillance and tumor marker monitoring. Claims with intervals shorter than what CMS recognizes as medically necessary are soft targets for post-payment review. Confirm your ordering providers are documenting the rationale for each order. |
| 4 | Separate your Medicare fee-for-service AFP billing from your Medicare Advantage billing. MA plans are not bound by CMS's coverage policy in the same way. Prior authorization requirements and coverage criteria can differ significantly. Build that distinction into your team's workflow. |
| 5 | Update your medical necessity documentation templates for AFP orders. Make sure each order captures the clinical indication, the relevant diagnosis, and the ordering provider's rationale. A well-documented order is your best defense against a claim denial. |
| 6 | If your practice bills AFP as part of a standing lab panel, loop in your compliance officer before May 15, 2026. Panel billing without individual medical necessity documentation for each component is a recognized audit target. Get a clear answer on whether your current practice holds up under this modified coverage policy. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Alpha-Fetoprotein Under This Policy
This policy does not include specific CPT, HCPCS, or ICD-10 codes in the available data. Do not use this post as a substitute for your MAC's local coverage determination.
How to Find the Right Codes
AFP testing is typically billed with a specific CPT code for the lab method used. Different methods — radioimmunoassay, enzyme immunoassay, and others — may carry different codes. Your lab billing team should already have these mapped, but confirm they align with what your MAC recognizes under the modified policy.
For ICD-10 diagnosis codes, the pairing should match the clinical indication exactly. HCC surveillance requires a different diagnosis code than active tumor monitoring or liver disease workup. Mismatched pairings are a primary driver of claim denial for lab tests.
Recommended Step: Pull your MAC's LCD for tumor markers and AFP specifically. Cross-reference it against your current CPT-to-ICD-10 pairing logic in your billing system. Any gaps should be resolved before May 15, 2026.
A Note on Local Coverage Determinations
AFP coverage under Medicare is often governed at the MAC level through a local coverage determination rather than a national coverage determination. That means the specific coverage criteria — including which diagnoses support billing, which test methods are covered, and what documentation is required — vary by region. Don't assume a policy summary you read for one MAC applies to yours.
If you work with multiple MAC jurisdictions, this is especially important. A claim that passes cleanly in one region may deny in another based on the local LCD. Alpha-fetoprotein billing is a place where regional variation genuinely matters.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.